Pharmaceutical Danish insulin giant Novo Nordisk appears to have backed down in its fight with the Greek government over the draconian drug price cuts - averaging 25% - imposed, which led to the company (as well as fellow Denmark-based LEO Pharma) to say that it would not supply some of its products (the so-called modern insulins or insulin analogues) to the country as it would not only be uneconomic, but would likely lead to parallel trading and calls for reductions in other markets (The Pharma Letter June 1). 15 June 2010